Presentation is loading. Please wait.

Presentation is loading. Please wait.

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

Published byLisa Lorentzen Modified over 5 years ago

Similar presentations

Presentation on theme: "High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired."— Presentation transcript:

1 High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study  Frank Siebenhaar, MD, Franziska Degener, Torsten Zuberbier, MD, Peter Martus, PhD, Marcus Maurer, MD  Journal of Allergy and Clinical Immunology  Volume 123, Issue 3, Pages (March 2009) DOI: /j.jaci Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Acquired Cold Urticaria Severity Index.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Study treatment group flow chart. S, Screening; R, randomization; V, visit; DL, desloratadine. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 The TempTest 2.0/2.1 device and example of placement on the forearm for the purpose of performing cold provocation tests. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 A, Representative illustration of digital 3-dimensional time-lapse photographic images of cold-induced wheal responses over time in 1 patient with ACU after treatment with placebo, 5 mg/d desloratadine, and 20 mg/d desloratadine for 7 days. B, Example of thermographic images of the cold-induced wheal response over 20 minutes in a patient with ACU treated with placebo, 5 mg/d desloratadine, and 20 mg/d desloratadine for 7 days. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 A, Box and whisker plots showing the wheal volume 15 minutes after cold provocation testing and after treatment with placebo (mean, mm3 [SD, mm3]), 5 mg of desloratadine (mean, mm3 [SD, mm3]), and 20 mg of desloratadine (mean, mm3 [SD, mm3]) every day for 7 days. Circles within the figures represent outlayers, and triangles illustrate extreme values. B, Mean wheal volume AUC over 90 minutes after cold provocation after treatment with placebo (mean, mm3 (SD, mm3]), 5 mg of desloratadine (mean, mm3 [SD, mm3]), and 20 mg of desloratadine (mean, mm3 [SD, mm3]) every day for 7 days. DL, Desloratadine. ∗∗∗P ≤ .001. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig 6 A, Box and whisker plots showing the CTTs elicited by using cold provocation at baseline and after treatment with placebo, 5 mg of desloratadine, and 20 mg of desloratadine every day for 7 days (assessed 10 minutes after provocation). B, CSTTs elicited by using cold provocation at baseline and after treatment with placebo, 5 mg of desloratadine, and 20 mg of desloratadine every day for 7 days. Circles within the figures represent outlayers, and triangles illustrate extreme values. DL, Desloratadine. ∗∗P ≤ .01; ∗∗∗P ≤ .001 (assessed 10 minutes after provocation). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired."

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.
Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,
Patient perspectives on the management of atopic dermatitis

Patient perspectives on the management of atopic dermatitis
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.
The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction  MyLinh Duong, MBBS, Reshma Amin, MD, Adrian J.

The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction  MyLinh Duong, MBBS, Reshma Amin, MD, Adrian J.

Similar presentations

Ads by Google